• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
118768 thigpen handouts
118768 thigpen handouts

...  Generic and predictable  Explainable  Early in therapy or with a  ...
Oasmia`s lead cancer product Paclical received market approval in
Oasmia`s lead cancer product Paclical received market approval in

... expectations in light of the information that is currently available, as well as assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from such statements. These risks and uncertainties include, but are not limited to, domestic and internationa ...
Controlled drug release
Controlled drug release

Controlled drug release
Controlled drug release

... Therapeutic index (TI) is described as the ratio of the maximum drug conc in the blood that can be tolerated to the minimum drug conc needed to produce a satisfactory clinical response. In some cases these ranges are narrow, resulting in small therapeutic index ...
VERISEQ® pharmaceutical grade gases. Nitrogen.
VERISEQ® pharmaceutical grade gases. Nitrogen.

Drug Interactions - St. James`s Hospital
Drug Interactions - St. James`s Hospital

... production of new metabolising enzymes and it frequently takes one to three weeks before their effects are at a maximum. In contrast enzyme inhibitors may have an effect on hepatic metabolism within 24 hours.2 Some interactions therefore occur almost immediately while others may take days, weeks or ...
Review of `square boxes`
Review of `square boxes`

... example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy ...
OTOMAX® Ointment
OTOMAX® Ointment

... gain, polydipsia, and/or polyuria. Prolonged use or overdosage may produce adverse immunosuppressive effects. Special Precautions for Use: Identification of infecting organisms should be made either by microscopic roll smear evaluation or by culture as appropriate. If overgrowth of nonsusceptible ba ...
past, present and future - National Cancer Registry Ireland
past, present and future - National Cancer Registry Ireland

Designer - RTI International
Designer - RTI International

... Analysis of ‘Bath Salts’ and other products suspected of containing mephedrone have revealed similar structural diversity being employed with these formulations. ‘Natural products’ and ‘dietary supplements’ are also becoming increasingly common and have been found to contain a variety of active ingr ...
MemberHealth - SilverScript
MemberHealth - SilverScript

... Staying healthy for less One way to save on prescription drug costs is to switch from a brand name drug to a generic drug used to treat the same condition. Generics are safe and effective because the Food and Drug Administration (FDA) requires that they have the same ...
See Important Disclosures and Disclaimers at the end of this report
See Important Disclosures and Disclaimers at the end of this report

... Pharmaceutical Co., Ltd, for Rolontis™ for the treatment of chemotherapy-induced neutropenia. The terms of the agreement give Spectrum the global rights for Rolontis™ (excluding Korea, China and Japan), and Spectrum has primary financial responsibility for the drug’s development. Spectrum is respons ...
0578 JAN 28  2OU3
0578 JAN 28 2OU3

... pain” or “joint disorders.” Rather we relied on the FDA statement at 65 FR 1030: FDA agrees that some minor pain relief claims may be appropriate structure/function claims for diets/y supplements. A claim that a product is intended to treat minor pain, without reference to any other conditions, symp ...
EACA - Blood CME Center
EACA - Blood CME Center

Basic Pharmacology
Basic Pharmacology

Injectable Fertility Medications
Injectable Fertility Medications

... Drug therapy initiated with samples will not be considered as meeting medical necessity for coverage for non-preferred or prior authorized medications. The preceding policy applies only to members for whom the above named pharmacy benefit medications are included on their covered formulary. Members ...
PHYSICo chemicaL PROPERTIES
PHYSICo chemicaL PROPERTIES

... (metabolized). The substances that result from metabolism (metabolites) may be inactive, or they may be similar to or different from the original drug in therapeutic activity or toxicity. Some drugs, called prodrugs, are administered in an inactive form, which is metabolized into an active form. ...
INDEX S.No Categories 1 Applications for Investigational New
INDEX S.No Categories 1 Applications for Investigational New

... (Carcinogenicity studies should be performed for all drugs that are expected to be clinically used for more than 6 months as well as for drugs used frequently in an intermittent manner in the treatment of chronic or recurrent conditions. However, completed rodent carcinogenicity studies are not need ...
Risk-based Monitoring: What it Needs to Be
Risk-based Monitoring: What it Needs to Be

Position Paper on the Importation of Foreign Prescription Drugs
Position Paper on the Importation of Foreign Prescription Drugs

... whether or not they have been tampered with or contaminated. In light of threatened terrorist attacks, the risk of tampering seems to be one of great significance. An added concern is that foreign brand-name drugs, including Canadian drugs, are not necessarily the same as their US counterparts. Diff ...
Revisão - Química Nova
Revisão - Química Nova

... to preserve biodiversity (chemical diversity libraries) and develop new drugs as an alternative to the production of the corresponding secondary metabolites. Even when bioactive natural products are not identified with the ideal potency or pharmacological properties for the development of new drugs, ...
reporting of adverse event reports the role of the medical
reporting of adverse event reports the role of the medical

... professionals are asked to report all suspected reactions to black triangle products to the CHM on yellow cards (see below). This includes any adverse or any unexpected event, however minor, which could conceivably be attributed to the medicine. Reports should be made despite uncertainty about a cau ...
the side effects of common psychiAtric drugs internAtionAl
the side effects of common psychiAtric drugs internAtionAl

... another new ADHD drug called Sparlon (Provigil). Between January 2000 and June 30, 2005, the FDA had received almost 1,000 reports of kids experiencing psychosis or mania while taking the drugs. The first panel recommended stronger warnings against stimulants, emphasizing these should appear on spec ...
PPT Food Additives & Cancer
PPT Food Additives & Cancer

...  The levels of tartrazine that where used in this study did ...
Instructions for Completing HUSC-RSC Form 1002
Instructions for Completing HUSC-RSC Form 1002

... doses to the total body, gonads, active blood-forming organs, critical organ, and lens of the eye. (The latter may be assumed to be equivalent to the total body dose unless specific eye uptake of the radioactive drug has been demonstrated or is expected). Submit a complete list, to include absorbed ...
< 1 ... 101 102 103 104 105 106 107 108 109 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report